Loading…
Disclosed for 26 months, Dec 2023 to Sep 2026.
UTI Innovation Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In August 2026 it disclosed 32 stocks worth ₹837 Cr, up ₹47.5 Cr from Jul 2026. Its largest positions were Eternal Limited (9.5%), Info Edge (India) Limited (9.0%), One 97 Communications Limited (6.2%); the ten largest together made up 55.6% of the portfolio, and Retailing was the biggest sector at 30.0% of its equity. Cash and debt stood at 2.9%. Compared with Jul 2026 the fund entered 2 new stocks and exited 1.
Top-10 weight is higher than 73% of peers
Holds more stocks than 18% of peers
Holds more cash than 43% of peers
Every line the fund disclosed, with the change against Jul 2026. Click a column to sort; click a company to see every fund that owns it.
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Compared with
Since Jul 2026, the weight rose most in Pharmaceuticals & Biotechnology (+1.8 pts) and Financial Technology (fintech) (+0.9 pts), and fell most in Retailing (−2.4 pts) and IT - Software (−1.1 pts).
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
| Sector | Jun 2025 | Feb 2026 | May 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|
| Retailing | 28.7% | 30.6% | 27.9% | 32.4% | 30.0% |
| IT - Software | 16.7% | 16.2% | 17.5% | 18.3% | 17.2% |
| Financial Technology (fintech) | 10.9% | 10.7% | 10.2% | 9.8% | 10.7% |
| IT - Services | 8.7% | 7.1% | 7.2% | 7.2% | 6.9% |
| Pharmaceuticals & Biotechnology | 1.4% | 3.6% | 5.1% | 4.6% | 6.4% |
| Transport Services | 3.4% | 4.4% | 4.4% | 4.3% | 4.6% |
| Leisure Services | 1.9% | 3.1% | 2.6% | 3.7% | 3.7% |
| Minerals & Mining | 3.7% | 3.9% | 3.6% | 3.4% | 3.6% |
| Entertainment | 4.9% | 3.4% | 2.9% | 3.3% | 3.4% |
| Electrical Equipment | 3.5% | 2.6% | 3.5% | 2.8% | 3.0% |
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.
| Apr 2026 | ₹740 Cr | 28 | 0 | 0 | 2.7% | 2.7% | — |
| Mar 2026 | ₹624 Cr | 28 | 0 | 1 | 2.5% | 2.5% | — |
| Feb 2026 | ₹689 Cr | 29 | 1 | 0 | 1.9% | 1.9% | — |
| Jan 2026 | ₹753 Cr | 28 | 0 | 0 | 4.2% | 4.2% | — |
| Dec 2025 | ₹829 Cr | 28 | 1 | 0 | 3.8% | 3.8% | — |
| Nov 2025 | ₹843 Cr | 27 | 0 | 0 | 2.4% | 2.4% | — |
| Oct 2025 | ₹863 Cr | 27 | 2 | 1 | 2.8% | 2.8% | — |
| Jun 2025 | ₹836 Cr | 26 | 2 | 0 | 3.7% | 3.7% | — |
| Apr 2025 | ₹760 Cr | 24 | 0 | 0 | 4.7% | 4.7% | — |
| Mar 2025 | ₹738 Cr | 24 | 0 | 1 | 2.4% | 2.4% | — |
| Feb 2025 | ₹710 Cr | 25 | 0 | 1 | 5.8% | 5.8% | — |
| Jan 2025 | ₹795 Cr | 26 | 0 | 0 | 3.8% | 4.5% | — |
| Dec 2024 | ₹873 Cr | 26 | 1 | 1 | 3.8% | 4.4% | — |
| Nov 2024 | ₹843 Cr | 26 | 0 | 0 | 6.5% | 7.1% | — |
| Oct 2024 | ₹810 Cr | 26 | 0 | 1 | 6.8% | 7.4% | — |
| Sep 2024 | ₹843 Cr | 27 | 0 | 0 | 5.3% | 5.9% | — |
| Aug 2024 | ₹821 Cr | 27 | 1 | 0 | 4.5% | 5.1% | — |
| Jul 2024 | ₹763 Cr | 26 | 2 | 0 | 5.1% | 5.8% | — |
| Apr 2024 | ₹645 Cr | 24 | 0 | 0 | 7.3% | 8.1% | — |
| Mar 2024 | ₹620 Cr | 24 | 0 | 0 | 5.5% | 6.2% | — |
| Dec 2023 | ₹550 Cr | 24 | 14.7% | 14.7% | — |